VPGMarketResearch's new report is a study of the major business opportunities emerging in the U.S. clinical chemistry and immunodiagnostic markets during the next five years. The report explores future trends in the U.S. market; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.
The report provides fiveyear volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables.
Rationale
The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
U.S. Market Overview
Estimates of facilities performing clinical chemistry and immunodiagnostic tests.
Test volume and sales projections.
Strategic Recommendations
New product development opportunities with significant market appeal.
Alternative market penetration strategies.
Potential market entry barriers and risks.
Market Segmentation Analysis
Comprehensive review of the market dynamics, trends, structure, size, growth, and key suppliers.
Test volume and sales forecasts for over 100 clinical chemistry,
TDM, endocrine, cancer, immunoprotein and abused drug assays, by market segment:
nbsp;nbsp;nbsp;nbsp; deg; Hospitals
nbsp;nbsp;nbsp;nbsp; deg; Commercial/Private Laboratories
nbsp;nbsp;nbsp;nbsp; deg; Physicians Offices/ Group Practices
Tests Analyzed in the Report
Routine Clinical Chemistry
Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin, Total, BUN Blood Urea Nitrogen, Calcium, Cardio CRP, Carbon Dioxide/Bicarbonate, Chloride, Cholesterol, Creatine Kinase CK, CKMB, Creatinine, CRP, Ferritin, GGT, Glucose, HDL Cholesterol, Homocysteine, Iron, LDH, LDL Cholesterol, Magnesium, Phosphorus, Potassium, Protein, Total, Sodium, Triglycerides, Troponin, Uric Acid.
Therapeutic Drug Monitoring TDM
Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin.
Endocrine Function
Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH, Prolactin, T3, T3 Uptake, Free T3, T4, Free T4, TBG, Testosterone, Thyroglobulin Ab, TPO Ab, TSH.
Tumor Markers and Special Chemistry
AFP, CA 153/2729, CA 199, CEA, Ferritin, Follate Folic Acid, Glycosylated Hemoglobin, HCG, 25Hydroxy Vitamin D2 and D3, Occult Blood, PAP, PSA, Thyroglobulin, Vitamin B12.
Immunoproteins
C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM, Immunofixation, Prealbumin, Protein Electrophoresis.
Drugs of Abuse
Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine, SD, Methadone, Methaqualone, Opiates, Phencyclidine PCP,
Propoxyphene, Tricyclic Antidepressants.
Current and Emerging Products
Analysis of current and emerging clinical chemistry and immunodiagnostic tests.
Review of current instrumentation technologies, and feature comparison of high, medium, and lowvolume/POC analyzers.
Technology Review
Assessment of current and emerging technologies, and their potential market applications.
Comprehensive lists of companies developing or marketing new technologies and products by test.
Competitive Assessments
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in RD.
The companies analyzed in the report include:
nbsp;nbsp; Abbott Laboratories
nbsp;nbsp; AdnaGen
nbsp;nbsp; Agilent Technologies
nbsp;nbsp; Bayer Healthcare
nbsp;nbsp; Beckman Coulter/Danaher
nbsp;nbsp; Biomedical Diagnostics
nbsp;nbsp; BioMerieux
nbsp;nbsp; BioRad
nbsp;nbsp; DiaSorin
nbsp;nbsp; Eiken
nbsp;nbsp; Fujirebio
nbsp;nbsp; Grifols
nbsp;nbsp; Instrumentation Laboratory
nbsp;nbsp; Kyowa Medex
nbsp;nbsp; Matritech/Alere
nbsp;nbsp; OrthoClinical Diagnostics
nbsp;nbsp; Quest Diagnostics
nbsp;nbsp; Roche
nbsp;nbsp; Siemens
nbsp;nbsp; Sysmex
nbsp;nbsp; Thermo Fisher
nbsp;nbsp; Tosoh
nbsp;nbsp; Wako
nbsp;nbsp; Wallac/PE
Contains 600 pages and 120 tables
NEXT ARTICLE